ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 2338 • ACR Convergence 2024

    TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis

    Lenche Kostadinova1, Brigid Wilson2, Hinnah Siddiqui2, Sara Behrens3, Angela Gupta4, Megan O'Mara3, Vicky Nahra5, Mahesha Makandura6, Shahdi Malakooti7, Maya Mattar8, David A Zidar1 and Donald D Anthony9, 1Louis Stokes VA Medical Center, cleveland, 2VA Northeast Ohio Healthcare System, Cleveland, 3CWRU, Cleveland, 4Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, 5University Hospitals Cleveland Medical Center, Cleveland, 6Henri Ford Medical Center, Detroit, 7MetroHealth at Case Western Reserve University, Cleveland, 8Louis Stokes VA medical Center, Mayfield Heights, OH, 9Louis Stokes VA Medical Center/Metro Health, Cleveland

    Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
  • Abstract Number: 0239 • ACR Convergence 2024

    Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Taissa M. Kasahara2, Asia-Sophia Wolf3, Kristin H. Bjørlykke4, Joseph Sexton5, Ingrid Jyssum5, Anne Therese Tveter5, Guri Solum3, Ingrid Fadum Kjønstad3, Andreas Lind6, Veselka Petrova Dimova-Svetoslavova6, Tore K. Kvien7, Jørgen Jahnsen8, Espen A. Haavardsholm1, Ludvig A. Munthe9, Sella A. Provan5, John Torgils Vaage9, Siri Mjaaland3, Kristin K. Jørgensen4, Gunnveig Grødeland9, Silje W. Syversen10 and Guro L. Goll10, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 3Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo, Norway, 7Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 8Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 9Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…
  • Abstract Number: 1015 • ACR Convergence 2024

    Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis

    Viet Bui1, Miguel Rodriguez2 and Sarah Ormseth3, 1Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, 2Texas Arthritis Center, El Paso, TX, 3The Lundquist Institute, Torrance, CA

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
  • Abstract Number: 2347 • ACR Convergence 2024

    Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment

    Thao Pham1, Raphaëlle Curmin2, BENOIT FLACHAIRE3, Florence Tubach2 and Corinne MICELI4, 1Assistance Publique-Hôpitaux de Marseille, Marseille, France, 2Cephepi, Sorbonne Université, INSERM, APHP, Paris, Paris, France, 3Aix Marseille University, Marseille, France, 4Université de Paris Cité, APHP, Paris, France

    Background/Purpose: Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to…
  • Abstract Number: 0240 • ACR Convergence 2024

    Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
  • Abstract Number: 1037 • ACR Convergence 2024

    Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

    Alice Terrett1, Athena Chin2, Mihye Kwon3, Samuel Whittle4 and Catherine Hill5, 1The Queen Elizabeth Hospital, Adelaide, Australia, 2Royal Adelaide Hospital, Tranmere, South Australia, Australia, 3Konyang University, College of Medicine, Daejeon, Republic of Korea, 4The Queen Elizabeth Hospital, Springfield, South Australia, Australia, 5The Queen Elizabeth Hospital, Woodville, South Australia, Australia

    Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
  • Abstract Number: 2359 • ACR Convergence 2024

    A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries

    Xenofon Baraliakos1, Ye Eun Lee2, Soyeon Park2, Young Nam Lee2, Megan Hughes3, Molly Edwards3, Emily Quiñones4 and Raj Sengupta5, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2Celltrion, Inc., Incheon, Republic of Korea, 3Adelphi Real World, Bollington, United Kingdom, 4Adelphi Real World, Macclesfield, United Kingdom, 5Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: CT-P13 SC, a new formulation of infliximab administered subcutaneously, has been approved by European Medicine Agency for the treatment of radiographic axial spondylarthritis (axSpA)…
  • Abstract Number: 0256 • ACR Convergence 2024

    Anti-TNF Therapy as a Potential Risk of Leishmania Infections

    Gloria Albaladejo Paredes1, Alicia Pérez González1, Esther Monleón Acosta1, Jose Andrés Rodríguez Fernández1, Pedro José Manuel Hernández1, Carlos Fernández Díaz1, María Rosario Oliva Ruíz1, Jose María Andreu Ubero2, Paloma Valentina Castillo Dayer2, Edgar Soriano Navarro3, David Pérez Parra4, Claudia Alejandra Capozzi2, María Rocío González Molina5, José Francisco Orts Paco6, José Pablo Serrano Serra6 and Vicente Cogolludo Campillo2, 1Hospital Universitario Santa Lucía, CARTAGENA, Spain, 2Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain, 3Hospital Universitario Santa Lucía, Murcia, Murcia, Spain, 4Hospital Universitario Santa Lucía, Murcia, 5Hospital Reina Sofía, Murcia, Murcia, Spain, 6Hospital Universitario Reina Sofía, Murcia, Murcia, Spain

    Background/Purpose: Leishmaniasis is an infectious disease caused by protozoon that occurs endemically in the Mediterranean Basin and South America and can affects to travellers to…
  • Abstract Number: 1377 • ACR Convergence 2024

    Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases

    Adrián Quevedo-Rodríguez1, Lucia Otero-Varela2, Fernando Sánchez-Alonso3, Yanira Pérez-Vera1, Javier Manero-Ruiz4, Cristina Campos-Fernández5, Sara Manrique-Arija6, Paloma Vela-Casasempere7, Antonio Mera-Varela8, César Díaz9, Atusa Movasat10, Blanca Garcia-Magallon11, Inmaculada Ros-Vilamajó12, Carolina Perez-Garcia13 and Isabel Castrejon14, and BIOBADASER working group., 1Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4Hospital Universitario Miguel Servet, Zaragoza, Spain, 5Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, 6Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 7Hospital General Universitario Alicante, Alicante, Spain, 8Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 9Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital Universitario Príncipe de Asturias, Madrid, Spain, 11Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, 12Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, 13Hospital del Mar, Barcelona, Spain, 14Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain

    Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
  • Abstract Number: 2598 • ACR Convergence 2024

    p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines

    Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA

    Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
  • Abstract Number: 0291 • ACR Convergence 2024

    Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center

    Victoria Furer1, Omer Kersh2, Mark Berman3, Ayelet Grupper2 and Ori Elkayam4, 1Tel Aviv Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Kefar sava, Israel, 4Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
  • Abstract Number: 1401 • ACR Convergence 2024

    Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis

    Omair Khan1, Syed Mujtaba Baqir2, Azka Naeem2, Muhammad Hashim khan2, Tharun Shyam2, Kseniya Slobodyanyuk3 and Anastasia Slobodnick4, 1Maimonides Medical Center, Council Bluffs, IA, 2Maimonides Medical Center, Brooklyn, NY, 3Maimonides Medical Center, Manhattan, NY, 4Northwell, Staten Island, NY

    Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
  • Abstract Number: 2619 • ACR Convergence 2024

    Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients

    Tali Eviatar1, Iftach Sagy2, Elad Brav2, Amir Bieber3, Victoria Furer4 and Ori Elkayam5, 1Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, 2Soroka Medical Cenrter, beer sheva, Israel, 3Emek Medical Center, Clalit Health Services, Raanana, Israel, 4Tel Aviv Medical Center, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
  • Abstract Number: 0356 • ACR Convergence 2024

    Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study

    Hubert Marotte1, Laure Gossec2, Vered ABITBOL3, Eric SENBEL4, Guillaume BONNAUD5, Xavier ROBLIN6, Yoram BOUHNIK7, Stéphane NANCEY8, Nicolas MATHIEU9, jérôme FILIPPI10, Lucine VUITTON11, Stéphane NAHON12, Azeddine Dellal12, Alice DENIS13, Caroline HABAUZIT13, Salim BENKHALIFA13 and Guillaume BOUGUEN14, 1Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 2Sorbonne Université, Paris, France, 3Cochin University Hospital, Paris, France, 4Medical practice, Marseille, Marseille, France, 5Ambroise Paré Clinic, Toulouse, France, 6Saint-Etienne University Hospital, Saint-Etienne, France, 7Institut des MICI, Paris IBD Center, Neuilly-Sur-Seine, France, 8Hospices Civils de Lyon, Lyon, France, 9Clinic of Cèdres, Echirolles, France, 10Saint-Jean Clinic, Cagnes sur Mer, France, 11Besançon university hospital, Besançon, France, 12Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 13Celltrion Healthcare France, Issy Les Moulineaux, France, 14Rennes University Hospital, Rennes, France

    Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…
  • Abstract Number: 1452 • ACR Convergence 2024

    Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)

    Timothy Brandon1, Rui Xiao2, Cassandra Muir1, Matthew Stoll3, Daniel Lovell4, Edward Oberle5, Nancy Chauvin6, Michael Francavilla7, Walter Maksymowych8 and Pamela Weiss9, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Nationwide Children's Hospital, Columbus, OH, 6The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, 7Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, 8University of Alberta, Edmonton, AB, Canada, 9Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology